Drugs /

oxs-3550

Back to Drugs List

Overview

NCI Definition [1]:
A trispecific killer engager (TriKE) molecule containing an anti-cluster of differentiation 16 (CD16; FcgammaRIII) single-chain variable fragment (scFv) to engage natural killer (NK) cells, an anti-CD33 scFv to engage myeloid cells and a human modified interleukin-15 (IL-15) linker, that links the two scFv, with potential immunomodulating and antineoplastic activities against CD33-expressing tumor cells. Upon administration of the CD16/IL15/CD33 TriKE OXS-3550, the simultaneous binding to CD16 on NK cells and CD33 on tumor cells will induce NK cell cytotoxicity specifically against CD33-expressing tumor cells. The cytokine IL-15 linker promotes NK cell proliferation, activity, survival and expansion. CD33 is expressed on normal non-pluripotent hematopoietic stem cells and is overexpressed on myeloid leukemia cells.

Clinical Trials

View Clinical Trials for oxs-3550

Oxs-3550 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating oxs-3550, 1 is phase 1/phase 2 (1 open).

CD33 Expression, Complex karyotype, and Monosomy 7 are the most frequent biomarker inclusion criteria for oxs-3550 clinical trials.

Acute myeloid leukemia, myelodysplastic syndromes, and refractory anemia with excess blasts are the most common diseases being investigated in oxs-3550 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Oxs-3550
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating oxs-3550 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
gtb-3550, oxs3550, gtb-3550 trike, gtb 3550, gtb3550, oxs 3550, oxis3550, cd16/il15/cd33 trispecific killer cell engager oxs-3550, cd16/il15/cd33 trike oxs-3550, cd16/il-15/cd33 161533 tri-specific killer engagers, 161533 trike, 161533
Drug Target(s) [2]:
CD33
NCIT ID [1]:
C151948

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.